Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTX NASDAQ:FPRX NASDAQ:GLYC NASDAQ:PTGX NASDAQ:XOMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10$0.08$0.01▼$0.72N/A1.271.32 million shs231,126 shsFPRXFive Prime Therapeutics$38.00$37.94$2.61▼$38.90$1.77B4.41.98 million shsN/AGLYCGlycoMimetics$0.16-6.6%$13.48$14.06▼$63.00$10.00M1.6267,672 shs1.05 million shsPTGXProtagonist Therapeutics$74.86+1.2%$64.51$33.31▼$93.25$4.60B2.21.65 million shs690,707 shsXOMAXOMA Royalty$35.17+2.6%$35.82$18.35▼$39.92$414.25M1.0249,616 shs31,308 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%0.00%FPRXFive Prime Therapeutics0.00%0.00%0.00%0.00%0.00%GLYCGlycoMimetics0.00%0.00%0.00%0.00%-99.13%PTGXProtagonist Therapeutics+1.18%-3.41%+13.51%+35.74%+60.68%XOMAXOMA Royalty+2.63%+1.38%-4.38%+36.16%+20.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTXAptinyx$0.10$0.08$0.01▼$0.72N/A1.271.32 million shs231,126 shsFPRXFive Prime Therapeutics$38.00$37.94$2.61▼$38.90$1.77B4.41.98 million shsN/AGLYCGlycoMimetics$0.16-6.6%$13.48$14.06▼$63.00$10.00M1.6267,672 shs1.05 million shsPTGXProtagonist Therapeutics$74.86+1.2%$64.51$33.31▼$93.25$4.60B2.21.65 million shs690,707 shsXOMAXOMA Royalty$35.17+2.6%$35.82$18.35▼$39.92$414.25M1.0249,616 shs31,308 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTXAptinyx0.00%0.00%0.00%0.00%0.00%FPRXFive Prime Therapeutics0.00%0.00%0.00%0.00%0.00%GLYCGlycoMimetics0.00%0.00%0.00%0.00%-99.13%PTGXProtagonist Therapeutics+1.18%-3.41%+13.51%+35.74%+60.68%XOMAXOMA Royalty+2.63%+1.38%-4.38%+36.16%+20.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTXAptinyx 0.00N/AN/AN/AFPRXFive Prime Therapeutics 0.00N/AN/AN/AGLYCGlycoMimetics 3.00BuyN/AN/APTGXProtagonist Therapeutics 2.83Moderate Buy$74.00-1.15% DownsideXOMAXOMA Royalty 2.25Hold$69.5097.61% UpsideCurrent Analyst Ratings BreakdownLatest PTGX, APTX, FPRX, XOMA, and GLYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025PTGXProtagonist TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/24/2025XOMAXOMA RoyaltyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/20/2025XOMAXOMA RoyaltyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$72.00 ➝ $96.0010/13/2025PTGXProtagonist TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/13/2025PTGXProtagonist TherapeuticsJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$112.0010/8/2025PTGXProtagonist TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.0010/8/2025XOMAXOMA RoyaltyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025PTGXProtagonist TherapeuticsJohnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.009/27/2025PTGXProtagonist TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTXAptinyx$1MN/AN/AN/A$0.57 per shareN/AFPRXFive Prime Therapeutics$14.87M119.01N/AN/A$4.13 per share9.20GLYCGlycoMimetics$10K1,000.25N/AN/A$0.08 per share1.94PTGXProtagonist Therapeutics$209.18M22.26$4.57 per share16.38$11.33 per share6.61XOMAXOMA Royalty$28.49M14.92N/AN/A$6.95 per share5.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTXAptinyx-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/AFPRXFive Prime Therapeutics-$137.20M-$3.92N/AN/AN/A-554.71%-75.84%-49.08%N/AGLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%N/APTGXProtagonist Therapeutics$275.19M$0.70106.94N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)XOMAXOMA Royalty-$13.82M-$1.55N/AN/AN/A-27.57%2.63%0.97%11/6/2025 (Estimated)Latest PTGX, APTX, FPRX, XOMA, and GLYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025PTGXProtagonist Therapeutics-$0.59N/AN/AN/A$5.41 millionN/A11/6/2025Q3 2025XOMAXOMA Royalty-$0.02N/AN/AN/A$11.47 millionN/A8/13/2025Q2 2025XOMAXOMA Royalty-$0.12$0.48+$0.60$0.44$9.39 million$13.13 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTXAptinyxN/AN/AN/AN/AN/AFPRXFive Prime TherapeuticsN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AXOMAXOMA RoyaltyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTXAptinyxN/AN/AN/AFPRXFive Prime TherapeuticsN/A5.355.35GLYCGlycoMimeticsN/A1.921.92PTGXProtagonist TherapeuticsN/A16.9716.97XOMAXOMA Royalty1.414.884.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTXAptinyxN/AFPRXFive Prime Therapeutics67.28%GLYCGlycoMimetics75.19%PTGXProtagonist Therapeutics98.63%XOMAXOMA Royalty95.92%Insider OwnershipCompanyInsider OwnershipAPTXAptinyx10.97%FPRXFive Prime Therapeutics6.40%GLYCGlycoMimetics8.70%PTGXProtagonist Therapeutics4.90%XOMAXOMA Royalty9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTXAptinyx12N/AN/ANot OptionableFPRXFive Prime Therapeutics8746.57 millionN/AOptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableXOMAXOMA Royalty1012.09 million10.99 millionOptionablePTGX, APTX, FPRX, XOMA, and GLYC HeadlinesRecent News About These CompaniesXOMA Royalty (NASDAQ:XOMA) Earns Sell (D-) Rating from Weiss Ratings2 hours ago | marketbeat.comMural Oncology shareholders approve acquisition by XRA 5 Corp.October 24 at 9:50 PM | msn.comMural Oncology Shareholders Approve Acquisition by XRA 5 Corp, a Subsidiary of XOMA Royalty CorporationOctober 24 at 4:30 PM | quiverquant.comQHead to Head Comparison: Compass Therapeutics (NASDAQ:CMPX) and XOMA Royalty (NASDAQ:XOMA)October 24 at 3:51 AM | americanbankingnews.comXOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200-Day Moving Average - Here's WhyOctober 23 at 4:50 AM | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Stock Rating Lowered by Zacks ResearchOctober 22 at 12:44 PM | marketbeat.comLAVA Therapeutics Stock Drops After Amended Deal With XOMA RoyaltyOctober 17, 2025 | msn.comXoma, Lava Therapeutics announce amendment to purchase agreementOctober 17, 2025 | msn.comXoma and Lava buyout cools with lower cash offer and closing conditionsOctober 17, 2025 | fiercebiotech.comFLAVA Therapeutics Amends Share Purchase AgreementOctober 17, 2025 | tipranks.comXOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase AgreementOctober 17, 2025 | globenewswire.comXOMA Royalty (NASDAQ:XOMA) Shares Pass Above Two Hundred Day Moving Average - Here's WhyOctober 15, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for XOMA Royalty (NASDAQ:XOMA)October 8, 2025 | marketbeat.comXOMA Royalty (NASDAQ:XOMA) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?October 7, 2025 | marketbeat.comXOMA Royalty PFD Update: Going Back To My Original Sell RatingsOctober 3, 2025 | seekingalpha.comXOMA Royalty PFD Update: Going Back To My Original Sell RatingsOctober 3, 2025 | seekingalpha.comXoma extends offer to acquire Lava TherapeuticsOctober 2, 2025 | msn.comLAVA Therapeutics Extends Tender Offer DeadlineOctober 2, 2025 | tipranks.comXOMA Royalty Corporation Extends Tender Offer for LAVA Therapeutics Shares Until October 17, 2025October 2, 2025 | quiverquant.comQXOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.October 2, 2025 | globenewswire.comQ3 Saw Some of the Highest-Value Biopharma Acquisitions of the Year So FarOctober 1, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTGX, APTX, FPRX, XOMA, and GLYC Company DescriptionsAptinyx NASDAQ:APTXAptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.Five Prime Therapeutics NASDAQ:FPRXFive Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.GlycoMimetics NASDAQ:GLYCGlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Protagonist Therapeutics NASDAQ:PTGX$74.86 +0.87 (+1.18%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$75.10 +0.24 (+0.32%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.XOMA Royalty NASDAQ:XOMA$35.17 +0.90 (+2.63%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$35.02 -0.16 (-0.44%) As of 10/24/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
